# A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

> **NCT06966154** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 68 (estimated)

## Conditions studied

- Natural Killer/T-cell Lymphoma
- Relapsed or Refractory Lymphoma Including ENKL

## Interventions

- **DRUG:** tislezumab
- **DRUG:** golidocitinib
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT06966154
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2027-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06966154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06966154, "A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06966154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*